Journal article
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
AJ Thompson, R Santoro, V Piazzolla, PJ Clark, S Naggie, HL Tillmann, K Patel, AJ Muir, KV Shianna, L Mottola, D Petruzzellis, M Romano, F Sogari, D Facciorusso, DB Goldstein, JG McHutchison, A Mangia
Hepatology | Published : 2011
DOI: 10.1002/hep.24068
Abstract
Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepatitis C virus (HCV). No data are available for genotype 2/3 HCV. We evaluated the association between the casual ITPA variants and on-treatment anemia in a well-characterized cohort of genotype 2/3 patients treated with variable-duration pegylated interferon alfa-2b (PEG-IFN-α2b) and RBV. Two hundred thirty-eight Caucasian patients were included in this retrospective study [185 (78%) with genotype 2 and 53 (22%) with genotype 3]. Patients were treated wi..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
[ "This work was supported by the Duke Clinical Research Institute (Alexander J. Thompson and Paul J. Clark), the Richard B. Boebel Family Fund (Alexander J. Thompson and Paul J. Clark), the Gastroenterology Society of Australia (Alexander J. Thompson and Paul J. Clark), the National Health and Medical Research Council of Australia (Alexander J. Thompson), and the Royal Australasian College of Physicians (Alexander J. Thompson).", "Dr. Thompson advises Roche and Merck; he also serves on the speaker's bureau of Merck. Dr. Thompson receives travel grants from Gilead. Dr. Naggie advises Vertex. Dr. Goldstein consults for Abbott and receives grants from GSK. Dr. McHutchison owns intellectual property rights in IL2bB and receives royalties on testing. Dr. McHutchison consults fir, advises, serves on the speaker's bureau of and receives grants from Merck/Schering." ]